SOPHiA GENETICS (NASDAQ:SOPH) Sees Large Volume Increase – Should You Buy?

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) saw strong trading volume on Monday . 110,773 shares traded hands during mid-day trading, a decline of 42% from the previous session’s volume of 191,681 shares.The stock last traded at $6.2450 and had previously closed at $5.87.

Analyst Upgrades and Downgrades

SOPH has been the subject of several research reports. BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. HC Wainwright began coverage on shares of SOPHiA GENETICS in a research note on Monday. They set a “buy” rating and a $12.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $9.00.

SOPHiA GENETICS Stock Up 8.2%

The stock has a market capitalization of $532.62 million, a PE ratio of -12.21 and a beta of 0.96. The stock’s 50-day moving average price is $5.23 and its two-hundred day moving average price is $5.02. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Insider Transactions at SOPHiA GENETICS

In related news, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.22, for a total transaction of $51,354.36. Following the completion of the transaction, the chief executive officer owned 670,651 shares of the company’s stock, valued at $3,500,798.22. This trade represents a 1.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Chairman Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock in a transaction on Friday, July 10th. The shares were sold at an average price of $5.62, for a total value of $47,770.00. Following the transaction, the chairman owned 3,532,622 shares of the company’s stock, valued at $19,853,335.64. The trade was a 0.24% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 176,711 shares of company stock worth $959,913. Company insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. increased its stake in SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after purchasing an additional 31,000 shares in the last quarter. Akre Capital Management LLC raised its holdings in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth approximately $49,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.